tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFs
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

GB:0MGB Stock Latest News

Genmab announces new results fom Phase 1b/2 EPCORE NHL-2 trial
The FlyGenmab announces new results fom Phase 1b/2 EPCORE NHL-2 trial
6d ago
GMAB
Genmab price target lowered to DKK 1,500 from DKK 1,700 at JPMorgan
PremiumThe Fly
Genmab price target lowered to DKK 1,500 from DKK 1,700 at JPMorgan
16d ago
GMAB
Genmab reports ‘encouraging anti-tumor activity’ for Rina-S in Phase 1/2 trial
PremiumThe Fly
Genmab reports ‘encouraging anti-tumor activity’ for Rina-S in Phase 1/2 trial
20d ago
GMAB
Genmab price target lowered to DKK 2,000 from DKK 2,300 at RBC Capital
PremiumThe Fly
Genmab price target lowered to DKK 2,000 from DKK 2,300 at RBC Capital
24d ago
GMAB
Genmab’s Promising Rina-S Developments Drive Buy Rating Amid Strong Initial Study Results
PremiumRatings
Genmab’s Promising Rina-S Developments Drive Buy Rating Amid Strong Initial Study Results
26d ago
GMAB
Genmab’s Rina-S: Promising Efficacy and Strategic Growth Potential in Endometrial Cancer Treatment
PremiumRatingsGenmab’s Rina-S: Promising Efficacy and Strategic Growth Potential in Endometrial Cancer Treatment
30d ago
GMAB
Bolt Biotherapeutics initiated with a Buy at Lake Street
Premium
The Fly
Bolt Biotherapeutics initiated with a Buy at Lake Street
1M ago
BOLT
GMAB
Genmab’s Strategic Forecast and Pipeline Potential Drive Buy Rating
Premium
Ratings
Genmab’s Strategic Forecast and Pipeline Potential Drive Buy Rating
1M ago
GMAB
Genmab price target lowered to $35 from $37 at H.C. Wainwright
PremiumThe Fly
Genmab price target lowered to $35 from $37 at H.C. Wainwright
1M ago
GMAB
Genmab’s Strong Financial Performance and Promising Pipeline Justify Buy Rating
PremiumRatings
Genmab’s Strong Financial Performance and Promising Pipeline Justify Buy Rating
1M ago
GMAB
Genmab’s Strong Performance Overshadowed by Patent Expiration Concerns and Competitive Challenges
PremiumRatings
Genmab’s Strong Performance Overshadowed by Patent Expiration Concerns and Competitive Challenges
1M ago
GMAB
Genmab upgraded to Buy from Hold at Nordea
PremiumThe Fly
Genmab upgraded to Buy from Hold at Nordea
1M ago
GMAB
Genmab reports Q1 revenue $715M vs. $603M last year
PremiumThe FlyGenmab reports Q1 revenue $715M vs. $603M last year
1M ago
GMAB
Genmab reaffirms FY25 guidance
Premium
The Fly
Genmab reaffirms FY25 guidance
1M ago
GMAB
Genmab price target lowered to DKK 1,990 from DKK 2,970 at HSBC
Premium
The Fly
Genmab price target lowered to DKK 1,990 from DKK 2,970 at HSBC
2M ago
GMAB
Genmab’s Strong Market Position and Growth Potential Justifies Buy Rating
PremiumRatings
Genmab’s Strong Market Position and Growth Potential Justifies Buy Rating
2M ago
GMAB
Genmab reports Q1 net sales of Darzalex of $3.24B
PremiumThe Fly
Genmab reports Q1 net sales of Darzalex of $3.24B
2M ago
JNJ
GMAB
Genmab price target lowered to $37 from $50 at H.C. Wainwright
PremiumThe Fly
Genmab price target lowered to $37 from $50 at H.C. Wainwright
2M ago
GMAB
Genmab’s Strong Financial Performance and Strategic Positioning Justify Buy Rating Despite Minor Setbacks
PremiumRatings
Genmab’s Strong Financial Performance and Strategic Positioning Justify Buy Rating Despite Minor Setbacks
2M ago
GMAB
Genmab downgraded to Underperform from Market Perform at Bernstein
PremiumThe FlyGenmab downgraded to Underperform from Market Perform at Bernstein
3M ago
GMAB
Genmab A/S Faces Sell Rating Amid Hexabody Setbacks and Darzalex Patent Concerns
Premium
Ratings
Genmab A/S Faces Sell Rating Amid Hexabody Setbacks and Darzalex Patent Concerns
3M ago
GMAB
Genmab announces EC marketing authorization for TIVDAK
Premium
The Fly
Genmab announces EC marketing authorization for TIVDAK
3M ago
GMAB

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >